Glaukos (GKOS) Truist Securities MedTech Conference 2026 summary

Business trends and reimbursement updates

• iDose drove nearly 60% U.S. glaucoma growth in Q1, with reimbursement frictions improving and only two MACs left to finalize professional fee schedules.

• Medicare fee-for-service, Medicare Advantage, and commercial channels are all being targeted, aiming for seamless clinical treatment regardless of insurance type.

• The eligible population for iDose is shifting, with potential for increased commercial mix as iDose is not tied to cataract surgery and younger patients are being treated.

LCD proposal and market impact

• The LCD process for iDose began earlier than expected, with strong support from societies and physicians during open meetings.

• Key LCD concerns include SLT step edits and combo MIGS restrictions, with clinical carve-outs needed for patients not eligible for SLT.

• There is a large pool of post-SLT failure patients, and even if LCD restrictions are finalized, the market for iDose remains significant.

• Marketing and targeting efforts will focus on identifying and treating SLT patients, leveraging a substantial prevalence pool.

Medicare Advantage and commercial access

• Medicare Advantage access is improving, but copay obligations remain a hurdle for most patients, with some relief later in the year as out-of-pocket maximums are met.

• Multiple pathways exist to achieve iDose growth targets, including increased utilization as more MACs finalize pro fees.